KR20220161413A - 코로나바이러스 감염의 억제 및 치료에 사용하기 위한 시알산 조성물 - Google Patents

코로나바이러스 감염의 억제 및 치료에 사용하기 위한 시알산 조성물 Download PDF

Info

Publication number
KR20220161413A
KR20220161413A KR1020227037491A KR20227037491A KR20220161413A KR 20220161413 A KR20220161413 A KR 20220161413A KR 1020227037491 A KR1020227037491 A KR 1020227037491A KR 20227037491 A KR20227037491 A KR 20227037491A KR 20220161413 A KR20220161413 A KR 20220161413A
Authority
KR
South Korea
Prior art keywords
sialic acid
use according
nana
acid
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227037491A
Other languages
English (en)
Korean (ko)
Inventor
얀 레머레이트
Original Assignee
라이프사이언스 에이에스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 라이프사이언스 에이에스 filed Critical 라이프사이언스 에이에스
Publication of KR20220161413A publication Critical patent/KR20220161413A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020227037491A 2020-04-01 2021-03-31 코로나바이러스 감염의 억제 및 치료에 사용하기 위한 시알산 조성물 Pending KR20220161413A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063003477P 2020-04-01 2020-04-01
US63/003,477 2020-04-01
PCT/IB2021/000200 WO2021198774A1 (en) 2020-04-01 2021-03-31 Sialic acid compositions for use in inhibiting and treating coronavirus infection

Publications (1)

Publication Number Publication Date
KR20220161413A true KR20220161413A (ko) 2022-12-06

Family

ID=76250375

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227037491A Pending KR20220161413A (ko) 2020-04-01 2021-03-31 코로나바이러스 감염의 억제 및 치료에 사용하기 위한 시알산 조성물

Country Status (9)

Country Link
US (3) US11813271B2 (https=)
EP (1) EP4125926A1 (https=)
JP (1) JP2023520703A (https=)
KR (1) KR20220161413A (https=)
CN (1) CN115461057A (https=)
AU (1) AU2021247584B2 (https=)
BR (1) BR112022019685A2 (https=)
CA (1) CA3173633A1 (https=)
WO (1) WO2021198774A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230226088A1 (en) * 2020-06-09 2023-07-20 The Texas A&M University System Therapeutics for treatment of covid-19 symptoms
WO2023104402A1 (en) 2021-12-09 2023-06-15 Frieslandcampina Nederland B.V. Milk fraction that inhibits covid-19 infection

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5976573A (en) 1996-07-03 1999-11-02 Rorer Pharmaceutical Products Inc. Aqueous-based pharmaceutical composition
EP2364139A2 (en) * 2008-11-10 2011-09-14 Life Science Nutrition AS Ngna compositions and methods of use
AU2010315024B2 (en) * 2009-11-06 2015-02-12 Nexbio, Inc. Methods, compounds and compositions for treatment and prophylaxis in the respiratory tract
CN111787925A (zh) * 2017-10-11 2020-10-16 生命科学股份有限公司 N-乙酰神经氨酸组合物和使用方法
CN111481560A (zh) * 2020-04-23 2020-08-04 菌维他(北京)医疗科技有限公司 唾液酸及衍生物在制备防治冠状病毒疾病的药品中的应用
CN111658631A (zh) 2020-06-11 2020-09-15 广东盛普生命科技有限公司 没食子酸及其衍生物和结构类似物在制备抗冠状病毒药物方面的应用

Also Published As

Publication number Publication date
US20260083762A1 (en) 2026-03-26
US20240148763A1 (en) 2024-05-09
JP2023520703A (ja) 2023-05-18
WO2021198774A1 (en) 2021-10-07
AU2021247584A1 (en) 2022-10-20
BR112022019685A2 (pt) 2022-11-22
CA3173633A1 (en) 2021-10-07
EP4125926A1 (en) 2023-02-08
CN115461057A (zh) 2022-12-09
US11813271B2 (en) 2023-11-14
US12390481B2 (en) 2025-08-19
US20230128687A1 (en) 2023-04-27
AU2021247584B2 (en) 2023-11-02

Similar Documents

Publication Publication Date Title
US11672814B2 (en) NGNA compositions and methods of use
US20260083762A1 (en) Sialic acid compositions for the use of inhibiting and treating coronavirus infection
EP3694524B1 (en) N-acetylneuraminic acid compositions and their use for inhibiting or treating ailments of the upper respiratory tract
US20190231686A1 (en) Methods for treating cystic fibrosis and other diseases affecting mucosal surfaces
EP3646858A1 (en) Encapsulated formulations
US20230165851A1 (en) 6'-methoxycinchonan-9-ols for the treatment of coronaviral infections
HK40084501A (en) Sialic acid compositions for use in inhibiting and treating coronavirus infection
EP2752194B1 (en) Natural antioxidant anti-influenza composition
RO138617A0 (ro) Compoziţie farmaceutică inovatoare sub formă de spray oral pentru sănătatea respiratorie
KR102838311B1 (ko) Rls 치료를 위한 님
KR20250098568A (ko) 진저롤을 유효성분으로 포함하는 신경병증성 통증 예방 또는 치료용 약학 조성물
WO2026072659A1 (en) Formulations of segmented filamentous bacteria-induced metabolites and methods of use thereof
US20230233456A1 (en) Compositions and methods for treating coronavirus
CN116546997A (zh) 基于低剂量精油的新治疗性组合物

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902